Derniers résultats 22 juil. 2026
Lonza Group AG
I · Analyse IA
En bref
Lonza manufactures medicines and biologics under contract for pharmaceutical companies that need specialized production capabilities. They operate three main business lines: Integrated Biologics (growing living cells to make complex drugs), Advanced Synthesis (manufacturing small molecule drugs and antibody-drug conjugates), and Specialized Modalities (cell and gene therapies, mRNA production). Essentially, they are the factory for companies that develop medicines but lack the specialized manufacturing infrastructure to produce them at scale [Yahoo Finance].
Lonza Group AG is a Swiss contract development and manufacturing organization (CDMO) that produces complex medicines for pharmaceutical and biotech companies, operating across biologics, small molecules, and specialized therapies like cell and gene treatments [Yahoo Finance]. The company generated CHF 6,5B in revenue but faces moderate financial concerns with negative free cash flow of CHF -204M and a debt load of 2,8x EBITDA [Yahoo Finance]. With 20 000 employees globally, Lonza is positioned in the high-growth biologics manufacturing sector but trades at a premium 37,5x price-to-earnings ratio [Yahoo Finance].
Lonza shows mixed financial health with solid profitability margins but concerning cash flow and elevated debt levels.
Score Sentinellis
4,2/10
Risques importants
Capitalisation boursière
CHF 34,1B
Chiffre d'affaires (12 mois)
CHF 6,5B
Explications
Comment nous lisons ces chiffres
Guides en langage clair · sans compte
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LirePiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LireAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LireII · Actualités récentes
Ce qui a fait bouger le cours
1 article · classés par pertinence
- Macro2026-05-19
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
Yahoo Finance
Premium · gratuit avec tout compte
Revenue contracted 0,7% year-over-year, indicating potential market headwinds or competitive pressures in Lonza's contract manufacturing segments [Yahoo Finance]
Risques
5
Opportunités
5
Signaux d'alerte
2
Direction
10
11 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Lonza Group AG
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 5 risques, 5 opportunités et 2 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
III · Entreprises similaires
À lire également
Même secteur · Santé — ou santé financière comparable
L'ajouter à votre liste ?